Companies/US/TARS

TARSUS PHARMACEUTICALS, INC.

Income flow

Annual
TARS 10-K Income StatementPeriod 2025-12-31Source 10-K
Reportable Segment$451MRevenue$451M+147% Y/YGross profit$421M+147% Y/YCost of revenue$31M

As-filed revenue segments and annual P&L (gross, opex, tax, net). Layout inspired by SankeyArt finance diagrams.

Revenue mix

2025-12-31 · 10-K · USD
By activity
By activity$451M
  • Reportable Segment$451M100.0%

Capital & dividends

YieldTrailing twelve-month dividends as a percent of the current share price (income yield).0.00%Trailing DPSCash dividends paid per share over the last twelve months (dividend per share, trailing).0Shares outTotal shares currently outstanding (issued and not retired).46.8MFloatShares available to trade — outstanding minus closely held (insiders, strategic holders).32.7M